Propel Bio Management, LLC Biotechnology

Propel Bio Management, LLC

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
APLT Applied Therapeutics Inc.	$423M	$30.7 Billion 19.89% of portfolio	6,567,858	Q2 2024 Added 7.46%
TCRX T Scan Therapeutics, Inc.	$85.9M	$12.2 Billion 7.92% of portfolio	2,087,139	Q4 2023 New
MDGL Madrigal Pharmaceuticals, Inc.	$4.44B	$12.1 Billion 7.82% of portfolio	43,032	Q1 2024 Added 43.29%
PHAT Phathom Pharmaceuticals, Inc.	$672M	$8.96 Billion 5.81% of portfolio	869,927	Q1 2024 Added 96.35%
AKRO Akero Therapeutics, Inc.	$1.43B	$7.69 Billion 4.99% of portfolio	327,752	Q1 2024 Added 227.58%
RNA Avidity Biosciences, Inc.	$2.2B	$7.29 Billion 4.73% of portfolio	178,500	Q4 2023 New
ARDX Ardelyx, Inc.	$908M	$6.85 Billion 4.44% of portfolio	924,583	Q2 2024 Added 55.61%
ABEO Abeona Therapeutics Inc.	$36.5M	$5.29 Billion 3.43% of portfolio	1,248,044	Q2 2024 New
FULC Fulcrum Therapeutics, Inc.	$164M	$4.65 Billion 3.02% of portfolio	750,000	Q4 2023 New
ATHA Athira Pharma, Inc.	$16.3M	$3.96 Billion 2.57% of portfolio	1,492,792	Q4 2023 New
VRCA Verrica Pharmaceuticals Inc.	$327M	$3.1 Billion 2.01% of portfolio	424,937	Q2 2024 New
KURA Kura Oncology, Inc.	$1.12B	$2.68 Billion 1.74% of portfolio	130,000	Q4 2023 New
SNDX Syndax Pharmaceuticals Inc	$1.07B	$1.71 Billion 1.11% of portfolio	83,259	Q1 2024 New
KYMR Kymera Therapeutics, Inc.	$2.53B	$1.68 Billion 1.09% of portfolio	56,359	Q4 2023 New
TRVI Trevi Therapeutics, Inc.	$172M	$775 Million 0.5% of portfolio	260,000	Q1 2024 New
CYBN Cybin Inc.	$1.67B	$230 Million 0.15% of portfolio	850,000	Q4 2023 New

Get notified when there are updates to the investment portfolio of Propel Bio Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Propel Bio Management, LLC with notifications on news.